Please assess the completion status of the following clinical trial:

Trial Title: First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients require histological biopsy and paraffin block more than 5mg from the original tumour or metastatic site to perform EGFR mutational analysis~* WHO Performance Status 0-2~* No prior chemotherapy, biological or immunological therapy/surgery~Exclusion Criteria:~* Any evidence of clinically active interstitial lung disease~* Newly diagnosed CNS metastases that have not yet been definitively treated with surgery /radiation~* Patients with previously diagnosed and treated CNS metastases or spinal cord compression

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gefitinib (Type: EXPERIMENTAL): Gefitinib 250mg tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).